Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21:808–20.

Finn RS, Qin S, Ikeda M, et al. IMbrave150 Investigators. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.

Jacob JS, Dutra BE, Garcia-Rodriguez V, et al. Clinical characteristics and outcomes of oral mucositis associated with immune checkpoint inhibitors in patients with cancer. J Natl Compr Canc Netw. 2021;19:1415–24.

Article  CAS  PubMed  Google Scholar 

Pinato DJ, Guerra N, Fessas P, et al. Immune-based therapies for hepatocellular carcinoma. Oncogene. 2020;39:3620–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dolladille C, Ederhy S, Sassier M, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020;6:865–71.

Article  PubMed  Google Scholar 

Westdorp H, Sweep MWD, Gorris MAJ, et al. Mechanisms of immune checkpoint inhibitor-mediated colitis. Front Immunol. 2021;12: 768957.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Acero Brand FZ, Suter N, Adam JP, et al. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab. J Immunother Cancer. 2018;6:1–5.

Article  Google Scholar 

Asan MF, Castelino RL, Babu SG, et al. Oral immune-related adverse events—current concepts and their management. Asia Pac J Oncol Nurs. 2021;8:604–9.

Article  PubMed  PubMed Central  Google Scholar 

Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer. 2017;25:1713–39.

Article  PubMed  Google Scholar 

Zhu AX, Finn RS, Edeline J, et al; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940–52.

Okiyama N, Katz SI. Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes. J Autoimmun. 2014;53:1–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu X, Tang H, Zhou Q, et al. Gut microbiota composition in patients with advanced malignancies experiencing immune-related adverse events. Front Immunol. 2023;14:1109281.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol. 2017;44:381–4.

Article  PubMed  Google Scholar 

Goldinger SM, Stieger P, Meier B, et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res. 2016;22:4023–9.

Article  CAS  PubMed  Google Scholar 

Pulito C, Cristaudo A, Porta CL, et al. Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res. 2020;39:210.

Article  PubMed  PubMed Central  Google Scholar 

Martins JO, Borges MM, Malta CE, Carlos AC, Crispim AA, Moura JF, Fernandes-Lima IJ, Silva PG. Risk factors for oral mucositis during chemotherapy treatment for solid tumors: a retrospective STROBE-guided study. Med Oral Patol Oral Cir Bucal. 2022;1(27):e319-329.

Article  Google Scholar 

Passat T, Touchefeu Y, Gervois N, et al. Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment. Bull Cancer. 2018;105:1033–41.

Article  PubMed  Google Scholar 

Fukushima T, Morimoto M, Kobayashi S, et al. Association between immune-related adverse events and survival in patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab. Oncologist. 2023;28:e526-533.

Article  PubMed  PubMed Central  Google Scholar